[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-333195-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-333195-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","exploration-of-ginkgo-biloba-leaves-on-non-small-cell-lung-cancer-based-on-network-pharmacology-and-molecular-docking","Exploration of Ginkgo biloba leaves on non-small cell lung cancer based on network pharmacology and molecular docking","","Pharmacological evidence suggests Ginkgo biloba leaves can inhibit neoplasms, yet its mechanism against non-small cell lung cancer (NSCLC) remains insufficiently clarified. Network pharmacology and molecular docking are used to identify Ginkgo active components, corresponding targets, and overlapping NSCLC targets. Protein–protein interaction networks, GO and KEGG pathway enrichment, and final Autodock Vina docking evaluate candidate drug–target interactions. Results highlight quercetin, luteolin, and kaempferol as key components potentially acting through Tp53, AKT1, and TNF, implicating PI3K/AKT and MAPK signaling pathways, offering theoretical support for clinical exploration.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/exploration-of-ginkgo-biloba-leaves-on-non-small-cell-lung-cancer-based-on-network-pharmacology-and-molecular-docking/333195/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/exploration-of-ginkgo-biloba-leaves-on-non-small-cell-lung-cancer-based-on-network-pharmacology-and-molecular-docking/333195.png","ImageObject",300,407,{"name":42,"@type":43},"Anda","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-29","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",12,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the main research goal of this study?","Question",{"text":63,"@type":64},"To explore the potential mechanism by which Ginkgo biloba leaves may treat non-small cell lung cancer using network pharmacology and molecular docking.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Which key Ginkgo biloba components are highlighted in the results?",{"text":68,"@type":64},"Quercetin, luteolin, and kaempferol are identified as key components potentially involved in NSCLC treatment.",{"name":70,"@type":61,"acceptedAnswer":71},"What signaling pathways and targets are suggested by the bioinformatic analysis?",{"text":72,"@type":64},"The study suggests involvement of PI3K/AKT and MAPK signaling pathways, with candidate targets including Tp53, AKT1, and TNF.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},333195,1790328331,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":116,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":4},962075006959,"https://ap-avatar.wpscdn.com/avatar/e0002397efbe92a78e?_k=1776741047341049297","®  \n Clinical Trial/Experimental Study   \nExploration of Ginkgo biloba leaves on non-small cell lung cancer based on network pharmacology and molecular docking  \nMingxiao Wang, MDa , Ruochen Li, MDa , Moiuqi Bai, MDa , Xun Zhou, PhDa ,*  \n\n| Abstract\u003Cbr>Background: Pharmacological studies have found Ginkgo biloba leaves have the effect of inhibiting neoplasms, it is clinically used in treating various neoplasms. However, the mechanism of Ginkgo biloba leaves in treating non-small cell lung cancer (NSCLC) remains unclear.\u003Cbr>Methods: The active components and corresponding targets of Ginkgo biloba leaves were obtained from the traditional Chinese medicine systems pharmacology database and analysis platform (TCMSP) database, and the targets of NSCLC were obtained from the GeneCards, OMIM, TTD, and DrugBank databases. The common targets of NSCLC and Ginkgo biloba leaves were obtained from VENNY 2.1.0. The STRING database was utilized to construct protein-protein intersections, by using the Cytoscape 3.7.1 software, the protein-protein intersection was optimized and the drug-disease network diagram was constructed. The DAVID database was utilized to perform GO and KEGG analysis. Finally, The Autodock Vina software was used to perform molecular docking of core components and targets.\u003Cbr>Results: The key components of Ginkgo biloba leaves in treating NSCLC include quercetin, luteolin, and kaempferol, which may act on Tp53, AKT1, and TNF. Bioinformatic annotation analysis results suggest that Ginkgo biloba leaves may implicated in PI3KAKT and MAPK signaling pathways. The molecular docking results show the firm affinity between key ingredients and targets. Conclusion: The potential mechanism of Ginkgo biloba leaves in treating NSCLC has been discussed in this study, which provides a theoretical basis for the clinical treatment of NSCLC and further experimental validation.\u003Cbr>Abbreviations: DL = drug-likeness, GO = gene ontology, KEGG = Kyoto Encyclopedia of Genes and Genomes, NSCLC = nonsmall cell lung cancer, OB = oral bioavailability, PPI = protein-protein interactions, TCM = traditional Chinese medicine, TCMSP = The traditional Chinese medicine systems pharmacology database and analysis platform. |\n| --- |\n| Keywords: Ginkgo biloba leaves, molecular docking, network pharmacology, non-small cell lung cancer |\n\n1. Introduction  \nLung cancer is a malignant tumor originating from the mucous membranes or glands of the bronchi of the lungs, it is one of the most common cancers and the leading cause of cancerrelated deaths. One statistic shows that in 2020, there were 480,000 new cases of lung cancer diagnosed in Europe, of which lung cancer caused 380,000 deaths. [1] According to the histopathological characteristics, lung cancer can be categorized into two major groups, including small-cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC), SCLC is a poorly differentiated and high-grade neuroendocrine neoplasm and accounts for 10% to 15% of lung cancers, NSCLC can be categorized into adenocarcinomas, large cell carcinomas, and squamous cell carcinoma, large-cell carcinoma, and squamous cell carcinoma, and accounts for the majority of all  \nlung cancers. [2] Most patients with early-stage NSCLC miss the best opportunity for treatment due to a lack of clinical presentations. [3] Currently, the main treatment modalities for NSCLC include surgery, chemotherapy, radiotherapy, immunotherapy, traditional Chinese medicine (TCM), etc. Though targeted therapy and immunotherapy for NSCLC have made great progress in the past two decades, the median overall survival for those metastatic NSCLC unfortunately still remains less than 3 years. [4]  \nIn recent years, Chinese medicine treatment for NSCLChas greatly attracted many researchers’ attention and many herbs have been found to exert significant inhibiting effects on lung cancers. Traditional Chinese medicine therapy of cancer has unique advantages such as low toxicity, cheapness, etc. Pang","cbCait96EW4pHQ10","https://ap.wps.com/l/cbCait96EW4pHQ10","pdf",2220566,"English","# Abstract\n# Introduction\n## Background and clinical context\n## Classification and treatment limitations\n# Methods and analysis (summary)\n## Active components and target collection\n## Network construction and functional enrichment\n## Molecular docking","[{\"question\":\"What is the main research goal of this study?\",\"answer\":\"To explore the potential mechanism by which Ginkgo biloba leaves may treat non-small cell lung cancer using network pharmacology and molecular docking.\"},{\"question\":\"Which key Ginkgo biloba components are highlighted in the results?\",\"answer\":\"Quercetin, luteolin, and kaempferol are identified as key components potentially involved in NSCLC treatment.\"},{\"question\":\"What signaling pathways and targets are suggested by the bioinformatic analysis?\",\"answer\":\"The study suggests involvement of PI3K/AKT and MAPK signaling pathways, with candidate targets including Tp53, AKT1, and TNF.\"}]","Exploration of Ginkgo biloba leaves on non-small cell lung cancer based on network pharmacology and molecular docking | PDF",1790001374,23]